EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieVergleichsstudie

Neuropathy Progression in Variant Transthyretin Amyloidosis: Comparison Between TTR Stabilizers and Gene Silencer Therapies

Catarina Falcão de Campos iD, Isabel de Castro iD, José Castro iD, Inês Losada Lopez, Juan Gonzalez Moreno iD, Isabel Conceição iD

Muscle & Nerve · 2026-12 · 74 (6) · 1546-1553

DOI: 10.1002/mus.70406 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Muscle & Nerve, online erschienen am 15.09.2026. Verfasst von Catarina Falcão de Campos und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Hospital Santa Maria, Lisbon, Portugal. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Prealbumin, Benzoxazoles, Polyneuropathies. Die Arbeit nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction/Aims Transthyretin ( TTR ) stabilizers and gene‐silencing therapies are approved for hereditary transthyretin‐mediated amyloidosis with polyneuropathy ( ATTRv ‐ PN ), but data from clinical practice in patients who transition between therapies due to disease progression remains limited. The primary aim of this study is to evaluate the effectiveness of patisiran in ATTRv ‐ PN patients who progressed despite prior treatment with tafamidis 20 mg.

Methods

We conducted a retrospective multicenter observational study including patients with ATTRV30M (p.V50M) with polyneuropathy who were initially treated with tafamidis 20 mg and subsequently switched to patisiran due to documented neuropathy progression. Patients had at least 12 months of follow‐up under each treatment. Neuropathy progression was assessed using the Neuropathy Impairment Score (NIS), neurophysiological composite scores, nutritional status, serum biomarkers, and patient‐reported outcomes.

Results

Thirty‐two patients (mean age 52 ± 14 years; mean disease onset 43 ± 23.5 years) were included. Median disease duration before treatment initiation was 1.8 ± 1.9 years. The mean duration of tafamidis and patisiran treatment was 4.5 ± 2.8 and 2.5 ± 2.3 years, respectively. The annual increase in NIS was significantly lower during patisiran treatment than during tafamidis (0.7 ± 3.9 vs. 3.9 ± 4.7; p = 0.004). Decline in neurophysiological parameters slowed after switching.

Discussion

In this cohort, patisiran attenuated neuropathy progression in patients who had deteriorated despite tafamidis. These findings highlight the importance of ongoing clinical monitoring to guide timely treatment optimization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid Neuropathies, FamilialPrealbuminBenzoxazolesPolyneuropathiesGenetic TherapyHumansMaleFemaleDisease ProgressionRetrospective StudiesMiddle AgedAdultAgedTreatment OutcomeRNA, Small Interfering

Stichwörter der Autor:innen

disease progressionhereditary transthyretin‐mediated amyloidosispatisiranpolyneuropathytafamidis

Substanzen

PrealbuminBenzoxazolestafamidispatisiranRNA, Small Interfering

Autor:innen und Institutionen

  • Department of Neurology, Hospital Santa Maria, Lisbon, Portugal.
  • Centro de Estudos Egas Moniz, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal.
  • Servicio de Medicina Interna, Hospital Universitario Son Llatzer, Instituto de Investigación Sanitaria Illes Balears, Palma, Spain.

ORCID-Profile: Catarina Falcão de Campos, Isabel de Castro, José Castro, Juan Gonzalez Moreno, Isabel Conceição

Zitieren

APA

Falcão de Campos, C., de Castro, I., Castro, J., Lopez, I. L., Moreno, J. G., & Conceição, I. (2026). Neuropathy Progression in Variant Transthyretin Amyloidosis: Comparison Between TTR Stabilizers and Gene Silencer Therapies. Muscle & Nerve, 74(6), 1546-1553. https://doi.org/10.1002/mus.70406

Vancouver

Falcão de Campos C, de Castro I, Castro J, Lopez IL, Moreno JG, Conceição I. Neuropathy Progression in Variant Transthyretin Amyloidosis: Comparison Between TTR Stabilizers and Gene Silencer Therapies. Muscle & Nerve. 2026;74(6):1546-1553. doi:10.1002/mus.70406

BibTeX
@article{FalcodeCampos2026,
  author = {Falcão de Campos, Catarina and de Castro, Isabel and Castro, José and Lopez, Inês Losada and Moreno, Juan Gonzalez and Conceição, Isabel},
  title = {Neuropathy Progression in Variant Transthyretin Amyloidosis: Comparison Between TTR Stabilizers and Gene Silencer Therapies},
  journal = {Muscle & Nerve},
  year = {2026},
  volume = {74},
  number = {6},
  pages = {1546--1553},
  doi = {10.1002/mus.70406}
}
Kostenlos starten →